Objective: To evaluate the prostate cancer detection rate in 45 patients who underwent transrectal ultrasound scan (TRUS) guided biopsies at King Abdul-Aziz University Hospital (KAUH), Jeddah, Kingdom of Saudi Arabia (KSA) and compare it with the previously reported national and international rates.
Methods: Forty-five charts reviewed for patients underwent TRUS guided biopsies in the period between July 1997 through to November 2002 at KAUH. Patients were entered in the study either as of high serum prostatic specific antigen (PSA) or abnormal digital rectal examination (DRE), or both. Cases with large prostate size or suspected elevation of PSA due to causes other than prostatic cancer was excluded from the study.
Results: Out of the 45 patients who underwent TRUS guided biopsy; cancer of the prostate was detected in 13 (28.8%). The cancer detection rate in patients presented with abnormal DRE alone was 7.6%, and was 15.3% in the group with elevated PSA but normal DRE (stage T1c). When PSA was elevated to 4-10 ng/ml TRUS guided biopsy detected cancer in 21.4%, elevation of PSA to10-20 ng/ml lead to cancer detection in 40% of the patients, and when PSA was above 20 ng/ml all cases were positive for cancer.
Conclusion: Cancer prostate is common in Western countries; national studies reported a low incidence of prostate cancer in KSA. Yet in our local patients using this precise method of investigation, our study confirms that the detection rate of prostate cancer through TRUS guided biopsies match the results of previously reported national studies and still lower than the international rates. Although the number of cases are small to draw solid and final conclusions; this study should stimulate further research and more reports on this important subject.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.
Cancer Imaging
January 2025
Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Background: Prostate cancer (PCa) is the leading cause of cancer-related morbidity and mortality in men worldwide. An early and accurate diagnosis is crucial for effective treatment and prognosis. Traditional invasive procedures such as image-guided prostate biopsy often cause discomfort and complications, deterring some patients from undergoing these necessary tests.
View Article and Find Full Text PDFConstruction of a clinically significant prostate cancer risk prediction model based on traditional diagnostic methods.
Front Oncol
December 2024
Urology 2nd Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Objectives: to construct a prediction model for clinically significant prostate cancer (csPCa) based on prostate-specific antigen (PSA) levels, digital rectal examination (DRE), and transrectal ultrasonography (TRUS).
Methods: We retrospectively analysed 1196 Asian patients who underwent transrectal ultrasound-guided biopsy (TRUSB) between June 2000 and February 2023. Patients were randomly divided into a training set of 837 cases (70%) and a validation set of 359 patients (30%).
Positive Predictive Value of High-Grade Prostate Imaging and Reporting Data System V2.1 Magnetic Resonance Imaging Findings for Prostate Cancer.
Ethiop J Health Sci
October 2024
Department of Radiology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Prostate cancer is a leading cause of cancer-related mortality among men, second only to lung cancer. Prostate magnetic resonance imaging (MRI) utilizing the Prostate Imaging and Reporting Data System (PI-RADS) v2.1 scoring system effectively stratifies patients by risk and correlates significantly with histopathological outcomes.
View Article and Find Full Text PDFOutcomes of Systematic Transrectal Ultrasound-Guided Prostate Biopsy Performed by a Surgical Care Practitioner and Implications for Resource-Poor Countries.
Cureus
November 2024
Urology, Peterborough City Hospital, Peterborough, GBR.
Introduction Prostate cancer remains the most prevalent cancer among men and continues to present a significant public health challenge globally. The disease's growing prevalence has heightened the demand for skilled professionals capable of obtaining histological samples for accurate diagnosis, as tissue biopsy remains the cornerstone for diagnosing prostate cancer. Surgical care practitioners have become integral to the surgical team, and their roles have expanded to include performing biopsies.
View Article and Find Full Text PDFThe number of involved regions by prostate adenocarcinoma predicts histopathology concordance between radical prostatectomy specimens and MRI/ultrasound-fusion targeted prostate biopsy.
Front Oncol
December 2024
Department of Urology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
Article Synopsis
- Using MRI-fusion guided prostate biopsy (PB) leads to better agreement with prostatectomy histopathology results compared to traditional 12-core TRUS biopsy, especially in patients with higher-risk prostate cancer.
- In a study involving 218 men diagnosed with prostate cancer, those who underwent MRI-fusion PB had a significantly higher concordance rate (73.1% vs. 42.9%) with the final pathology from surgery.
- The research highlighted that the number of cancer-involved regions in the prostate is an important factor influencing concordance, indicating that MRI-fusion techniques enhance diagnostic accuracy and treatment planning for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!